Mirikizumab – a new option in the treatment of inflammatory bowel diseases
DOI:
https://doi.org/10.56782/pps.262Keywords:
mirikizumab, IL-23, ulcerative colitisAbstract
ABSTRACT
Mirikizumab is a humanized monoclonal antibody targeting the p19 subunit of interleukin IL-23. Over the past few years, it has been the subject of clinical trials as a potential new treatment for inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. Additionally, mirikizumab has been investigated in clinical trials as a potential treatment for plaque psoriasis. The results of clinical trials for mirikizumab in treating ulcerative colitis led to its approval in the European Union, the United States, Canada, and Japan for treating adult patients with moderately to severely active ulcerative colitis. Despite promising clinical trial results, mirikizumab has not yet been approved for the treatment of Crohn's disease. This review focuses on summarizing the findings from clinical trials of mirikizumab in the treatment of inflammatory bowel diseases. Information is sourced from scientific papers available on PubMed, by searching for "mirikizumab" and “IL-23” and published to March 2024, as well as from published results of clinical trials concerning mirikizumab.
Downloads
References
Tan, Z.Y.; Bealgey, K.W.; Fang, Y.; Gong, Y.M.; Bao, S. Interleukin-23: immunological roles and clinical implications. Int. J. Biochem. Cell Biol. 2009, 41(4), 733-5 DOI: 10.1016/j.biocel.2008.04.027 DOI: https://doi.org/10.1016/j.biocel.2008.04.027
Duvallet, E.; Semerano, L.; Assier, E.; Falgarone, G.; Boissier, M.C.; Interleukin-23: a key cytokine in inflammatory diseases. Ann. Med. 2011, 43(7), 503- 11, DOI:10.3109/07853890.2011.577093 DOI: https://doi.org/10.3109/07853890.2011.577093
Tian, Z.; Zhao, Q.; Teng, X. Anti-IL23/12 agents and JAK inhibitors for inflammatory bowel disease. Front. Immunol. 2024, 15, Art. No: 1393463. DOI: 10.3389/fimmu.2024.1393463 DOI: https://doi.org/10.3389/fimmu.2024.1393463
Tang, C.; Chen, S.; Qian, H.; Huang, W. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology 2012, 135(2), 112-124. DOI: 10.1111/j.1365-2567.2011.03522.x DOI: https://doi.org/10.1111/j.1365-2567.2011.03522.x
Danese, S.; Furfaro, F.; Vetrano, S. Targeting S1P in Inflammatory Bowel Disease: New Avenues for Modulating Intestinal Leukocyte Migration. J. Crohns Colitis 2017, 12(suppl_2), 678-S86. DOI:10.1093/ecco-jcc/jjx107 DOI: https://doi.org/10.1093/ecco-jcc/jjx107
Aggarwal, S.; Gurney, A.L. IL-17: prototype member of an emerging cytokine family. J. Leukoc. Biol. 2002, 71(1), 1-8. DOI: 10.1189/jlb.71.1.1 DOI: https://doi.org/10.1189/jlb.71.1.1
Aggarwal, S.; Ghilardi, N.; Xie, M.H.; de Sauvage, F.J.; Gurney, A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 2003, 278(3), 1910-1914. DOI:10.1074/jbc.M207577200 DOI: https://doi.org/10.1074/jbc.M207577200
Steere, B.; Beidler, C.; Martin, A.; Bright, S.; Kikly, K.; Benschop, R.J. Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23. J. Pharmacol. Exp. Ther. 2023, 387(2), 180-187. DOI:10.1124/jpet.122.001512 DOI: https://doi.org/10.1124/jpet.122.001512
Lees, C.W.; Barrett, J.C.; Parkes, M.; Satsangi, J. New IBD genetics: common pathways with other diseases. Gut 2011, 60(12), 739-753 DOI:10.1136/gut.2009.199679 DOI: https://doi.org/10.1136/gut.2009.199679
Levin, A.A.; Gottlieb, A.B. Specific targeting of interleukin-23p19 as effective treatment for psoriasis. J. Am. Acad. Dermatol. 2014, 70(3), 555-561. DOI: 10.1016/j.jaad.2013.10.043 DOI: https://doi.org/10.1016/j.jaad.2013.10.043
Elson, C.O.; Cong, Y.; Weaver, C.T.; Schoeb, T.R.; McClanahan, T.K.; Fick, R.B. et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 2007, 132(7), 2359-70. DOI:10.1053/j.gastro.2007.03.104 DOI: https://doi.org/10.1053/j.gastro.2007.03.104
Hammerhøj, A.; Boye, T.L.; Langholz, E.; Nielsen, O.H. Mirikizumab (Omvoh™) for ulcerative colitis. Trends Pharmacol. Sci. 2024, 45(3), 281-2. DOI:10.1016/j.tips.2024.01.001 DOI: https://doi.org/10.1016/j.tips.2024.01.001
Feuerstein, J.D.; Cheifetz, A.S. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin. Proc. 2014, 89(11), 1553-1563. DOI:10.1016/j.mayocp.2014.07.002 DOI: https://doi.org/10.1016/j.mayocp.2014.07.002
Tontini, G.E.; Vecchi, M.; Pastorelli, L.; Neurath, M.F.; Neumann, H. Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives. World J. Gastroenterol. 2015, 21(1), 21-46. DOI:10.3748/wjg.v21.i1.21 DOI: https://doi.org/10.3748/wjg.v21.i1.21
Rao, S.S.; Holdsworth, C.D.; Read, N.W. Symptoms and stool patterns in patients with ulcerative colitis. Gut 1988, 29(3), 342-5. DOI:10.1136/gut.29.3.342 DOI: https://doi.org/10.1136/gut.29.3.342
Raine, T.; Bonovas, S.; Burisch, J.; Kucharzik, T.; Adamina, M.; Annese, V. et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J. Crohns Colitis 2021, 16(1), 2-17. DOI:10.1093/ecco-jcc/jjab178 DOI: https://doi.org/10.1093/ecco-jcc/jjab178
Danese, S.; Fiocchi, C. Etiopathogenesis of inflammatory bowel diseases. World J. Gastroenterol. 2006, 12(30), 4807-12. DOI:10.3748/wjg.v12.i30.4807 DOI: https://doi.org/10.3748/wjg.12.4807
Dragasevic, S.; Stankovic, B.; Sokic-Milutinovic, A.; Milosavljevic, T.; Milovanovic, T.; Lukic, S. et al. Importance of TLR9-IL23-IL17 axis in inflammatory bowel disease development: Gene expression profiling study. Clin. Immunol. 2018, 197, 86-95. DOI:10.1016/j.clim.2018.09.001 DOI: https://doi.org/10.1016/j.clim.2018.09.001
Sandborn, W.J.; Ferrante, M.; Bhandari, B.R.; Berliba, E.; Feagan, B.G.; Hibi, T. et al. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. Gastroenterology 2020, 158(3), 537-549.e10. DOI: 10.1053/j.gastro.2019.08.043 DOI: https://doi.org/10.1053/j.gastro.2019.08.043
Sandborn, W.J.; Sands, B.E.; Vermeire, S.; Leung, Y.; Guo, X.; Modesto, I. et al. Modified Mayo score versus Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program. Therap. Adv. Gastroenterol. 2022, 15, Art. No: 7562848221136331. DOI: 10.1177/17562848221136331 DOI: https://doi.org/10.1177/17562848221136331
II phase clinical trial of mirikizumab in UC [accesed and cited 2024 27.07]. Available from: https://clinicaltrials.gov/study/NCT02589665.
Sandborn, W.J.; Ferrante, M.; Bhandari, B.R.; Berliba, E.; Hibi, T.; D'Haens, G.R. et al. Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis. Clin. Gastroenterol. Hepatol. 2022, 20(1), 105-115.e14. DOI: 10.1016/j.cgh.2020.09.028 DOI: https://doi.org/10.1016/j.cgh.2020.09.028
Badanie LUCENT-1 - III faza badań klinicznych mirikizumabu w leczeniu UC [accesed and cited 2024 27.07]. Available from: https://clinicaltrials.gov/study/NCT03518086.
Efficacy and Safety of Mirikizumab as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Study. Gastroenterol. Hepatol. 2022; 18(4 Suppl 1), 7-8.
D’Haens, G.; Kobayashi, T.; Morris, N.; Lissoos, T.; Hoover, A.; Li, X. et al. OP26 Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study. J. Crohns Colitis 2022, 16(Supplement_1), i028-i029. DOI: 10.1093/ecco-jcc/jjab232.025 DOI: https://doi.org/10.1093/ecco-jcc/jjab232.025
D’Haens, G.; Dubinsky, M.; Kobayashi, T.; Irving, P.M.; Howaldt, S.; Pokrotnieks, J. et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 2023, 388(26), 2444-2455. DOI:10.1056/NEJMoa2207940 DOI: https://doi.org/10.1056/NEJMoa2207940
LUCENT-2 Badanie podtrzymujące z zastosowaniem mirikizumabu u uczestników z umiarkowanie do ciężko aktywną postacią wrzodziejącego zapalenia jelita grubego. [accesed and cited 2024 27.07]. Available from: https://clinicaltrials.gov/study/NCT03524092
Kobayashi, T.; Matsuoka, K.; Watanabe, M.; Hisamatsu, T.; Hirai, F.; Milata, J. et al. Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies. Intest. Res. 2024, 22(2), 172-85. DOI:10.5217/ir.2023.00043 DOI: https://doi.org/10.5217/ir.2023.00043
LUCENT -3. Badanie oceniające długoterminową skuteczność i bezpieczeństwo mirikizumabu u uczestników z umiarkowanie do ciężko aktywną postacią wrzodziejącego zapalenia jelita grubego. [accesed and cited 2024 27.07]. Available from: https://clinicaltrials.gov/study/NCT03519945.
Sands, B.E.; D’Haens, G.; Clemow, D.B.; Irving, P.M.; Johns, J.T.; Hunter, T. et al. Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflamm. Bowel Dis. 2024, 30(6), 1044-1045. DOI: 10.1093/ibd/izae024 DOI: https://doi.org/10.1093/ibd/izae096
SHINE1 - Badanie mirikizumabu u dzieci i nastolatków z wrzodziejącym zapaleniem jelita grubego [accesed and cited 2024 27.07] Available from: https://clinicaltrials.gov/study/NCT04004611.
PK, Efficacy, and Safety of Mirikizumab as Induction Therapy in Pediatric Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 2 SHINE-1 Study. Gastroenterol. Hepatol. 2023, 19(7 Suppl 3), 8-9.
Informacja producenta dotycząca dopuszczenia mirikizumabu (Omvoh) na terenie USA we wskazaniu do leczenia umiarkowanej i ciężkiej postaci UC u osób dorosłych [accesed and cited 2024 27.07]. Available from: https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-omvohtm-mirikizumab-mrkz-first-class
Informacja ze strony Europejskiej Agencji Leków (EMA) dotycząca leku Omvoh (mirikizumab) [accesed and cited 2024 27.07]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/omvoh
Decyzja o dopuszczeniu leku Omvoh(mirikizumab) na terenie Kanady do leczenia umiarkowanego i ciężkiego UC [accesed and cited 2024 27.07]. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD1695821197450.
Decyzja Japońskiej Agencji Leków o dopuszczeniu leku Omvoh (mirikizumab) do obrotu na terenie Japonii do leczenia umiarkowanej i ciężkiej postaci UC u dorosłych [accesed and cited 2024 27.07]. Available from: https://www.pmda.go.jp/PmdaSearch/iyakuDetail/GeneralList/23994A5.
Shanahan, F. Crohn's disease. The Lancet. 2002, 359(9300), 62-9. DOI: 10.1016/S0140-6736(02)07284-7 DOI: https://doi.org/10.1016/S0140-6736(02)07284-7
Baumgart, D.C.; Sandborn, W.J. Crohn's disease. The Lancet. 2012, 380(9853), 1590-605.DOI:10.1016/S0140-6736(12)60026-9 DOI: https://doi.org/10.1016/S0140-6736(12)60026-9
SERENITY - badanie skuteczności mirikizumabu u pacjentów z aktywną chorobą Crohna [accesed and cited 2024.27.07]. Available from: https://clinicaltrials.gov/study/NCT02891226.
Avedillo-Salas, A.; Corral-Cativiela, S.; Fanlo-Villacampa, A.; Vicente-Romero, J.; The Efficacy and Safety of Biologic Drugs in the Treatment of Moderate-Severe Crohn's Disease: A Systematic Review. Pharmaceuticals (Basel) 2023, 16(11), ARt. No: 1581. DOI: 10.3390/ph16111581 DOI: https://doi.org/10.3390/ph16111581
Sands, B.E.; Peyrin-Biroulet, L.; Kierkus, J.; Higgins, P.D.R.; Fischer, M.; Jairath, V. et al. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease. Gastroenterology 2022, 162(2), 495-508. DOI:10.1053/j.gastro.2021.10.050 DOI: https://doi.org/10.1053/j.gastro.2021.10.050
VIVID-1 - badanie skutecznośći mirikizumabu w leczeniu dorosłych pacjentów z umiarkowaną do ciężkiej postacią choroby Crohna [accesed and cited 2024 27.07]. Available from: https://clinicaltrials.gov/study/NCT03926130.
Aslam, M.; Ali, M.H.; Irfan, H.; Mirikizumab: A promising breakthrough in Crohn's disease treatment. Health Sci. Rep. 2024, 7(8), Art. No: e2294. DOI:10.1002/hsr2.2294 DOI: https://doi.org/10.1002/hsr2.2294
Ferrante, M.; Danese, S.; Chen, M.; D'Haens, G.; Ghosh, S.; Hisamatsu, T. et al. OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 study. J. Crohns Colitis 2024, 18(Supplement_1), i7-i9. DOI: 10.1093/ecco-jcc/jjad212.0005 DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0005
Jairath, V.; Sands, B.E.; Bossuyt, P.; Farraye, F.; Ferrante, M.; Hisamatsu, T. et al. OP35 Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate to severe Crohn’s disease: Results from the phase 3 VIVID 1 study. J. Crohns Colitis 2024, 18(Supplement_1), i62-i4. DOI:10.1093/ecco-jcc/jjad212.0035 DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0035
VIVID-2 - Długoterminowe badanie rozszerzone mirikizumabu u uczestników z chorobą Leśniowskiego-Crohna [accesed and cited 2024 27.07]. Available from: https://clinicaltrials.gov/study/NCT04232553.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Jakub Olszewski, Katarzyna Kozon, Magdalena Sitnik, Katarzyna Herjan, Karolina Mikołap, Bartłomiej Gastoł, Maciej Bara, Piotr Armański, Marcin Sawczuk
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
